XML 39 R28.htm IDEA: XBRL DOCUMENT
v3.23.1

Collaborations, Licensing Agreements and Other Agreements - Additional Information (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 31, 2023 | May 31, 2020 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | Dec. 31, 2023 | May 31, 2023 | Feb. 28, 2023 | Jan. 01, 2023 | Oct. 07, 2022
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  | $ 12,435,000 | $ 9,170,000 |  |  |  |  |  |
Accrued and Other Current Liabilities |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Expenses |  |  | 400,000 |  |  |  |  |  |  |
License and Service [Member] |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront Payment |  |  | 1,200,000 |  |  |  |  |  |  |
Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront Payment |  |  |  |  |  |  | $ 500 |  |  |
License Agreement |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Obligation to be paid |  |  | $ 2,000,000 |  |  |  |  |  |  |
Payment term |  |  | 3 years |  |  |  |  |  |  |
Payment commencement date |  |  | 2018-08 |  |  |  |  |  |  |
License maintenance fee |  | $ 33,000 | $ 10,000 |  |  |  |  |  |  |
Total milestone payments |  |  | 21,000,000 |  |  |  |  |  |  |
Amounts due to agreement |  |  | 0 |  |  |  |  |  |  |
Sponsored Research Agreements |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Obligation to be paid |  |  | 12,560,000 |  |  |  |  |  |  |
Master Translational Research Services Agreement |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Research and development expense |  |  | 1,511,000 | $ 635,000 |  |  |  |  |  |
Oxford Biomedica |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Obligation to be paid |  |  |  |  | $ 4,000,000 |  |  |  |  |
Research and development expense |  |  |  |  | $ 1,100,000 |  |  |  |  |
Nanjing IASO Biotherapeutics Co., Ltd. [Member] |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Total milestone payments |  |  | 1,000,000 |  |  |  |  |  |  |
Upfront Payment |  |  | $ 162,000,000 |  |  |  |  |  |  | $ 2,500,000
Autolus Holdings [Member] |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront Payment |  |  |  |  |  |  |  | $ 800 | $ 1,200,000 |
Autolus Holdings [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Total milestone payments | $ 15,000,000 |  |  |  |  |  |  |  |  |
Autolus Holdings [Member] | Maximum [Member] | License and Service [Member] |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Total milestone payments | $ 12,000,000 |  |  |  |  |  |  |  |  |
Autolus Holdings [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |
Collaborations, Licensing Agreements And Other Agreements [Line Items] |  |  |  |  |  |  |  |  |  |
Upfront Payment |  |  |  |  |  | $ 100 |  |  |  |

X
- Definition Collaborations licensing agreements and other agreements. + References No definition available. + Details
Name: | caba_CollaborationsLicensingAgreementsAndOtherAgreementsLineItems
Namespace Prefix: | caba_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative agreement payments due. + References No definition available. + Details
Name: | caba_CollaborativeAgreementPaymentsDue
Namespace Prefix: | caba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition License maintenance fee. + References No definition available. + Details
Name: | caba_LicenseMaintenanceFee
Namespace Prefix: | caba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | caba_MilestonePayments
Namespace Prefix: | caba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Obligation to be paid, commencement date. + References No definition available. + Details
Name: | caba_ObligationToBePaidCommencementDate
Namespace Prefix: | caba_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment of obligation, term. + References No definition available. + Details
Name: | caba_PaymentOfObligationTerm
Namespace Prefix: | caba_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment + References No definition available. + Details
Name: | caba_UpfrontPayment
Namespace Prefix: | caba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments. + References No definition available. + Details
Name: | us-gaap_ContractualObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of expense classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4,6) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.7) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 + Details
Name: | us-gaap_OtherExpenses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 912 -SubTopic 730 -Section 25 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=caba_AccruedAndOtherCurrentLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SupplyCommitmentAxis=caba_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SupplyCommitmentAxis=caba_SponsoredResearchAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SupplyCommitmentAxis=caba_MasterTranslationalResearchServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SupplyCommitmentAxis=caba_OxfordBiomedicaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SupplyCommitmentAxis=caba_NanjingIasoBiotherapeuticsCoLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SupplyCommitmentAxis=caba_AutolusHoldingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |